Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.

Aim: To investigate the real‐world effectiveness of pharmacological treatments (buprenorphine, methadone) of opioid use disorder (OUD). Design A nation‐wide, register‐based cohort study. Setting: Sweden. Participants: All residents aged 16–64 years living in Sweden using OUD medication from July 200...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 117; no. 6; pp. 1683 - 1692
Autores principales: Heikkinen, Milja, Taipale, Heidi, Tanskanen, Antti, Mittendorfer‐Rutz, Ellenor, Lähteenvuo, Markku, Tiihonen, Jari
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Jun2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156737799&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 156737799
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Jun2022
      vid: 117
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        156737799
        155099394
        156737799
        156737799
        10.1111/add.15814
        156737799
      ppf: 1683
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.
      aug:
        au:
          Heikkinen, Milja
          Taipale, Heidi
          Tanskanen, Antti
          Mittendorfer‐Rutz, Ellenor
          Lähteenvuo, Markku
          Tiihonen, Jari
        affil: Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland
      sug:
        subj:
          Narcotics Adverse Effects
          Substance Use Disorders Drug Therapy
          Buprenorphine Therapeutic Use
          Methadone Therapeutic Use
          Drug Efficacy Evaluation
          Human
          Prospective Studies
          Sweden
          Persons with Substance Use Disorders
          Adolescence
          Young Adult
          Adult
          Middle Age
          Male
          Female
          Descriptive Statistics
          Drugs, Prescription
          Inpatients
          Outpatients
          Cause of Death
          Sick Leave
          Persons with Disabilities
          Pensions
          Hospitalization
          Substance Use Disorders Mortality
          Cox Proportional Hazards Model
          Multiple Regression
          Confidence Intervals
          Risk Assessment
          Death Risk Factors
          Comparative Studies
          Nonexperimental Studies
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Aim: To investigate the real‐world effectiveness of pharmacological treatments (buprenorphine, methadone) of opioid use disorder (OUD). Design A nation‐wide, register‐based cohort study. Setting: Sweden. Participants: All residents aged 16–64 years living in Sweden using OUD medication from July 2005 to December 2016 (n = 5757, 71.8% men) were identified from registers of prescriptions, inpatient and specialized outpatient care, causes of death, sickness absence and disability pensions. Measurements Main outcome: hospitalization due to OUD. Secondary outcomes: hospitalization due to any cause; death due to all, natural and external causes. Mortality was analyzed with between‐individual multivariate‐adjusted Cox hazards regression model. Recurrent outcomes, such as hospitalizations, were analyzed with within‐individual analyses to eliminate selection bias. OUD medication use versus non‐use was modelled with PRE2DUP (from prescription drug purchases to drug use periods) method. Findings Buprenorphine [hazard ratio (HR) = 0.73, 95% confidence interval (CI) = 0.54–0.97] and methadone (HR = 0.74, 95% CI = 0.59–0.93) use were associated with significantly lower risk of OUD hospitalization, but not any‐cause hospitalizations, compared with the time‐periods when the same individual did not use OUD medication. The use of buprenorphine and methadone were both associated with significantly lower risk of all‐cause mortality (HR = 0.45, 95% CI = 0.34–0.59; HR = 0.51, 95% CI = 0.41–0.63, respectively), compared with non‐use of both medications. Similar results were found for risk of mortality due to external causes (HR = 0.39; 95% CI = 0.27–0.54; HR = 0.40; 95% CI = 0.29–0.53, respectively), but not for mortality due to natural causes. The risk of OUD hospitalization and all‐cause mortality was decreased in all duration categories of studied medications (< 30, 31–180, 181–365 and >365 days), except for methadone use less than 30 days. Conclusions: The use of buprenorphine and methadone are both associated with a significantly lower risk of hospitalization due to opioid use disorder and death due to all and external causes, when compared with non‐use.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N